Patents Assigned to Nabi
-
Patent number: 6875445Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.Type: GrantFiled: October 24, 2002Date of Patent: April 5, 2005Assignee: Nabi BiopharmaceuticalsInventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
-
Patent number: 6773891Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 30, 2002Date of Patent: August 10, 2004Assignee: NABI BioPharmaceuticals, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6756361Abstract: A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. faecalis and E. faecium, and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infection by clinically significant (pathogenic) Enterococcus isolates. The antigens and antibodies generated to the antigens are also useful in diagnostic assays.Type: GrantFiled: October 14, 1997Date of Patent: June 29, 2004Assignee: NABIInventors: Ali Ibrahim Fattom, Ramesh K. Sood, Sara E. Shepherd
-
Patent number: 6677310Abstract: The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded (“fat”) heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus.Type: GrantFiled: April 21, 1999Date of Patent: January 13, 2004Assignees: Nabi, University of Maryland Baltimore CountyInventors: Ramachandra S. Hosmane, Ramesh K. Sood
-
Publication number: 20030165950Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: December 30, 2002Publication date: September 4, 2003Applicant: NABI, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6537559Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.Type: GrantFiled: September 24, 2001Date of Patent: March 25, 2003Assignee: NABIInventor: Ali Ibrahim Fattom
-
Patent number: 6518031Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: February 16, 2001Date of Patent: February 11, 2003Assignee: NABIInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20020131969Abstract: Compositions and kits comprising combinations of &bgr;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &bgr;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: ApplicationFiled: February 22, 2002Publication date: September 19, 2002Applicant: NABIInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6355625Abstract: Compositions and kits comprising combinations of &bgr;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &bgr;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: GrantFiled: September 14, 1999Date of Patent: March 12, 2002Assignee: NabiInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6294177Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.Type: GrantFiled: May 10, 1999Date of Patent: September 25, 2001Assignee: NABIInventor: Ali Ibrahim Fattom
-
Patent number: 6232082Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 1, 1998Date of Patent: May 15, 2001Assignee: NabiInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6194161Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection.Type: GrantFiled: June 22, 1998Date of Patent: February 27, 2001Assignee: NabiInventors: Ali Ibrahim Fattom, Atulkumar Induprasad Patel
-
Patent number: 5961975Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.Type: GrantFiled: June 7, 1995Date of Patent: October 5, 1999Assignee: NabiInventors: Ali Ibrahim Fattom, Walter W. Karakawa, D. Craig Wright
-
Patent number: 5866140Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.Type: GrantFiled: December 22, 1994Date of Patent: February 2, 1999Assignee: NabiInventors: Ali Ibrahim Fattom, Walter W. Karakawa, deceased, D. Craig Wright
-
Patent number: 5843912Abstract: The present invention relates to compositions comprising analogues of purine nucleosides containing a ring-expanded ("fat") heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivatives of such compositions, as well as methods of use thereof. In particular, these compositions may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis.Type: GrantFiled: August 23, 1995Date of Patent: December 1, 1998Assignees: Universy of Maryland, NabiInventors: Ramachandra Hosmane, Barry Burns
-
Patent number: 5770208Abstract: A negatively-charged S. aureus antigen contains .beta.-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection.Type: GrantFiled: September 11, 1996Date of Patent: June 23, 1998Assignee: NABIInventors: Ali Ibrahim Fattom, Atulkumar Induprasad Patel